{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:11:40Z","timestamp":1792876300270,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"35","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>\n              Eligible patients had an Eastern Cooperative Oncology Group performance status of \u22641 and a T2-4aN0-1M0 stage with &gt;50% urothelial carcinoma histology and were ineligible for or refused cisplatin-based chemotherapy. Patients received four cycles of nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg\/m\n              <jats:sup>2<\/jats:sup>\n              once on days 1 and 8, every 3 weeks, followed by RC, and then adjuvant nivolumab 360 mg once every 3 weeks \u00d7 13 cycles. The primary end point was the pathologic complete response (CR) rate (ypT0N0). Secondary end points were major pathologic response (ypT\u22641N0), safety, event-free survival (EFS), and overall survival.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Thirty-one patients were enrolled from December 2021 to June 2023; 19 (61.3%) had a cT2 stage, two (6.5%) had N1 stage, and 16 (51.6%) had a variant histology. Five patients (16.1%) received less than four full courses of neoadjuvant treatment because of treatment-related adverse events (TRAEs). Grade 3\/4 TRAEs occurred in eight patients (25.8%). Twenty-eight patients underwent RC, and three refused RC after evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT). The trial met its primary end point: 10 patients (32.3%; 95% CI, 16.7 to 51.4) achieved an ypT0N0 response. By including those who underwent reTURBT, 22 (70.9%; 95% CI, 55 to 87) achieved an ypT\u22641N0-x response. After a median follow-up of 12 months (range, 5-22), two patients had a disease relapse after surgery. The 12-month EFS was 89.8% (95% CI, 79.5 to 100).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco.24.00576","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T19:59:18Z","timestamp":1725652758000},"page":"4196-4205","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":23,"title":["First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04876313","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":true,"given":"Chiara","family":"Mercinelli","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":true,"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Mattorre","sequence":"additional","affiliation":[{"name":"Cellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":true,"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-7821","authenticated-orcid":true,"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-4320","authenticated-orcid":true,"given":"Laura L.","family":"Cogrossi","sequence":"additional","affiliation":[{"name":"Cellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":true,"given":"Brigida A.","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano A.","family":"Patan\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4185-2475","authenticated-orcid":true,"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7359-3112","authenticated-orcid":true,"given":"Giovanni L.","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8908-0817","authenticated-orcid":true,"given":"Chiara","family":"Re","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-0743","authenticated-orcid":true,"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-614X","authenticated-orcid":true,"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9690-8624","authenticated-orcid":true,"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6246","authenticated-orcid":true,"given":"Dean C.","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":true,"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"},{"name":"SUNY Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-2569","authenticated-orcid":true,"given":"Matteo","family":"Bellone","sequence":"additional","affiliation":[{"name":"Cellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":true,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.008"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.003"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70275-8"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02199-y"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5012"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.022"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4517"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1013"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.448"},{"key":"e_1_3_9_19_2","article-title":"Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy","volume":"40","author":"Gupta S","year":"2022","unstructured":"Gupta S, Gibb E, Sonpavde GP, et al: Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol 40, 2022 (suppl 6; abstr 528)","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00363"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01485"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01003"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.041"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70162-1"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.012"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16191"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.012"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.075"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.03.044"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01132-2"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.12.019"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa076"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2011.642418"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000472"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.438"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T22:59:54Z","timestamp":1733439594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":42,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2024,12,10]]}},"alternative-id":["10.1200\/JCO.24.00576"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00576","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"2024-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}